Reported by Ars Technica •
4 Wire-neutral provisional

✓ No loaded language, vague sourcing, or framing detected.

Moderna and Merck report success in Phase 3 melanoma trial for mRNA cancer vaccine

Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 trial for melanoma, involving 1,137 patients. The trial compared the vaccine combined with Keytruda to Keytruda alone, conducted in a double-blind and placebo-controlled format.

Companies
Moderna Merck

Our neutral summary

Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 trial for melanoma, involving 1,137 patients. The trial compared the vaccine combined with Keytruda to Keytruda alone, conducted in a double-blind and placebo-controlled format.

Read the full story at Ars Technica

The reporting belongs to Ars Technica; we don't reproduce it. You can compare how outlets framed this story below.

Annotating as

Notes are private: only you can see them.

No note attached

of yours on this article.

Original vs. Neutral

Original Headline

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Neutral Headline

Moderna and Merck report success in Phase 3 melanoma trial for mRNA cancer vaccine